ALDEYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.93 USD | -0.25% |
|
+1.81% | +11.97% |
| 04-25 | Transcript : Aldeyra Therapeutics, Inc. - Special Call | |
| 04-04 | North American Morning Briefing : Focus Turns to -2- | DJ |
| Sales 2024 * | 28.43M 2.27B | Sales 2025 * | 24.78M 1.98B | Capitalization | 233M 18.67B |
|---|---|---|---|---|---|
| Net income 2024 * | -1M -79.96M | Net income 2025 * | -23M -1.84B | EV / Sales 2024 * | 8.21 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.42 x |
| P/E ratio 2024 * |
-78.6
x | P/E ratio 2025 * |
-10.4
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aldeyra Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -0.25% | ||
| 1 week | +1.81% | ||
| Current month | +20.18% | ||
| 1 month | +20.18% | ||
| 3 months | +29.28% | ||
| 6 months | +167.35% | ||
| Current year | +11.97% |
1 week
3.83
4.18
1 month
3.134.97
Current year
2.714.97
1 year
1.4211.97
3 years
1.4213.18
5 years
1.4215.95
10 years
1.4216.70
| Managers | Title | Age | Since |
|---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 31/08/05 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 30/11/19 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 30/04/09 |
Martin Joyce
BRD | Director/Board Member | 70 | 30/09/13 |
Ben Bronstein
BRD | Director/Board Member | 74 | 31/05/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.93 | -0.25% | 267,876 |
| 25/04/24 | 3.94 | 0.00% | 462,606 |
| 24/04/24 | 3.94 | +0.77% | 570,606 |
| 23/04/24 | 3.91 | -0.51% | 452,310 |
| 22/04/24 | 3.93 | +1.81% | 372,085 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.93
USD
Average target price
9.571
USD
Spread / Average Target
+143.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.97% | 233M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALDX Stock
